NINGBO INNO PHARMCHEM CO.,LTD. is at the forefront of oncological innovation, proudly presenting Vandetanib, a potent and highly selective anti-cancer pharmaceutical chemical. As a leading active pharmaceutical ingredient (API), Vandetanib represents a significant leap forward in the field of targeted cancer therapy. Our commitment to excellence ensures that we provide this critical compound as a high-purity, white to off-white powder, meeting the most stringent in-house and international standards, with a purity assay consistently exceeding 99%.

The paradigm of cancer treatment has been dramatically reshaped by the advent of targeted therapies. Unlike traditional cytotoxic chemotherapy that affects both cancerous and healthy cells, targeted therapies like Vandetanib are designed to interfere with specific molecules that are crucial for cancer growth, progression, and spread. This precision approach not only enhances efficacy but also tends to offer a more manageable side-effect profile, marking a new era of personalized medicine. Vandetanib is a prime example of this innovation, functioning as a powerful oral kinase inhibitor. Its sophisticated mechanism of action allows it to simultaneously block several key signaling pathways that tumors exploit to survive and proliferate.

The primary mechanism of Vandetanib involves the inhibition of multiple receptor tyrosine kinases (RTKs). Specifically, it targets the Vascular Endothelial Growth Factor Receptor (VEGFR), the Epidermal Growth Factor Receptor (EGFR), and the REarranged during Transfection (RET) proto-oncogene. This multi-targeted approach is what makes Vandetanib a formidable agent against certain types of cancer.

Inhibition of VEGFR: Angiogenesis, the formation of new blood vessels, is a critical process for tumor growth. Tumors require a dedicated blood supply to receive the oxygen and nutrients necessary for their expansion. Vandetanib potently inhibits VEGFR-2, a key mediator of angiogenesis. By blocking this pathway, it effectively cuts off the tumor's lifeline, starving it of essential resources and hindering its ability to grow and metastasize.

Inhibition of EGFR: The EGFR pathway plays a vital role in cell proliferation, survival, and differentiation. In many cancers, this pathway is overactive, leading to uncontrolled cell division. Vandetanib targets and inhibits EGFR, disrupting these aberrant growth signals and inducing a halt in the cancer cell cycle, which can lead to apoptosis (programmed cell death).

Inhibition of RET: The RET proto-oncogene is particularly significant in the context of medullary thyroid carcinoma (MTC). Mutations in the RET gene are a key driver in the majority of hereditary and sporadic MTC cases. Vandetanib's ability to selectively inhibit RET kinase activity makes it an exceptionally effective treatment for this specific malignancy. By blocking the mutated RET protein, it directly counteracts the primary driver of the cancer's growth.

The clinical application of Vandetanib is most prominently established in the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable, locally advanced, or metastatic disease. MTC is a rare but aggressive form of thyroid cancer originating from the parafollicular C-cells of the thyroid gland. For patients with advanced MTC, treatment options were historically limited. Vandetanib has emerged as a standard of care in this setting, demonstrating significant improvements in progression-free survival in landmark clinical trials. Its oral, once-daily administration offers a convenient and effective long-term management strategy for this challenging disease.

At NINGBO INNO PHARMCHEM CO.,LTD., we understand the critical importance of quality and consistency in pharmaceutical manufacturing. Our Vandetanib is produced under strict quality control protocols to ensure it meets the highest specifications. The physical and chemical properties of our product are meticulously verified:
Appearance: A white or off-white crystalline powder.
Purity (HPLC): Guaranteed to be between 98.0% and 102.0%, with typical batches achieving an assay of 99.8% or higher.
Water Content: Maintained at or below 0.50%.
Heavy Metals: Kept to a minimum, not exceeding 10ppm.
Related Substances: Total impurities are controlled to be less than 1.00%, with any single impurity not exceeding 0.10%.
These specifications highlight our dedication to providing a superior quality product for research and pharmaceutical formulation.

As the landscape of cancer therapy continues to evolve towards more precise and personalized treatments, the demand for high-quality, reliable APIs is paramount. NINGBO INNO PHARMCHEM CO.,LTD. is a premier manufacturer and supplier of Vandetanib. We are committed to supporting the pharmaceutical industry with our top-tier products. If you are looking to buy Vandetanib for your research or manufacturing needs, we are your trusted partner. We encourage you to reach out to us to inquire about the price and availability. When you decide to purchase Vandetanib, choosing a reputable supplier is crucial to ensure the integrity of your final product. As a leading Vandetanib manufacturer, we provide comprehensive support and documentation to facilitate your development and production processes, ensuring you receive a product of unparalleled quality and purity.